Boston's HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B

Boston's HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B

Source: 
BioSpace
snippet: 

Two years after Boston-based HotSpot Therapeutics launched, the company has secured $65 million in Series B funding to advance the development of its allosteric therapies that target “regulatory hotspots” in the body into the clinic.